Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies.

ABSTRACT: The purpose of this study was to assess the safety, tolerability, and preliminary anti-tumor activity of experimental medication NZV930 alone and when combined with PDR001 and/or NIR178, in patients with advanced cancers

DISEASE(S): Ovarian Cancer,Colorectal Cancer Microsatellite Stable (mss),Renal Cell Carcinoma (rcc),Pancreatic Ductal Adenocarcinoma (pdac),Triple Negative Breast Neoplasms,Triple Negative Breast Cancer (tnbc),Carcinoma, Renal Cell,Non-small Cell Lung Cancer (nsclc),Metastatic Castration Resistant Prostate Cancer (mcrpc)

PROVIDER: 2274758 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies.

Project description:To characterize the safety and tolerability of NIS793 as single agent and in combination with PDR001 and to identify recommended doses for future studies.

| 2228562 | ecrin-mdr-crc

Phase Ib Study of PDR001 in Combination With Regorafenib in Adult Patients With Previously Treated Metastatic Colorectal Cancer

Project description:This was a phase Ib study of PDR001 in combination with regorafenib in adult patients with previously treated metastatic microsatellite stable (MSS) colorectal cancer. The study assessed primarily the safety and tolerability of PDR001 in combination with regorafenib.

| 2238875 | ecrin-mdr-crc

Stand alone study

Project description:Stand alone study

| PRJNA671252 | ENA

Phase I study of the antiprogrammed cell death-1 Ab spartalizumab (PDR001) in Japanese patients with advanced malignancies.

Project description:Spartalizumab is a humanized IgG4/? mAb directed against human programmed cell death-1 (PD-1). In this phase I study, we investigated safety, pharmacokinetics, preliminary antitumor activity, and toxicity of spartalizumab in patients with advanced malignancies. Patients (n = 18) with a range of tumor types received spartalizumab i.v. at doses of 1, 3, and 10 mg/kg every 2 weeks until disease progression, unacceptable toxicity, or discontinuation at the discretion of the investigator or patient. Most patients (61%) had received five or more prior lines of therapy. No dose-limiting toxicities were reported and, hence, the maximum tolerated dose was 10 mg/kg or more. Pharmacokinetics in Japanese patients aligned with those reported in a global dose-escalation study. The safety profile was consistent with other approved anti-PD-1 mAbs; the most common drug-related adverse events were maculopapular rash (22%), followed by malaise and increased blood alkaline phosphatase (11% each). Partial responses were reported in two patients (11%), one with transitional cell carcinoma and the other with hepatocellular carcinoma. In conclusion, this study confirmed the safety of spartalizumab given at a dose of up to 10 mg/kg every 2 weeks in Japanese patients with cancers.

| S-EPMC7893979 | biostudies-literature

Gene Expression Profile In Presence of p53 alone, p47 alone, or both

Project description:H1299 cells (p53-/-) were transfected with plasmid constructs expressing p53 alone, p47 alone or both, and gene expression profile was probed

2016-11-02 | GSE74305 | GEO

Dabrafenib + Trametinib + PDR001 In Colorectal Cancer

Project description:This research study is studying a combination of drugs as a possible treatment for metastatic colorectal cancer characterized by BRAF V600E mutation. The names of the study drugs involved in this study are: * Dabrafenib * Trametinib * PDR001

| 2283931 | ecrin-mdr-crc

Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors.

Project description:This is a phase I/Ib, open label study. The escalation portion will characterize the safety and tolerability of DKY709 and DKY709 in combination with PDR001 in subjects with NSCLC or melanoma who have received prior anti-PD-1/PD-L1 therapy, or subjects with NPC. After the determination of the MTD/RD for a particular treatment arm, dose expansion will further assess safety, tolerability, PK/PD, and anti-tumor activity of each regimen at the MTD/RD.

| 2301104 | ecrin-mdr-crc

Transcription profiling of mouse leydig tumor cell line stimulated with either human chorionic gonadotropin alone or with bisphenol A, an endrocrine disrupting chemical

Project description:A mouse leydig tumour cell line (mLTC-1) was grown in culture and stimulated with either human chorionic gonadotropin (hCG, 10 ng/ml) alone or hCG & bisphenol A (BPA, an endrocrine disrupting chemical, 10 uM) for three hours. Cells from triplicate plates were harvested, RNA extracted, labelled and hybridised to Affymetrix Mouse genome 430 2.0 arrays. Preliminary work by RT-PCR had shown that stimulation of the cell line by BPA resulted in changes in gene expression in the spermatogenesis pathway at this time point.

2008-01-01 | E-MIMR-282 | biostudies-arrayexpress

Cohesin regulates alternative splicing alone or with BRD4

Project description:Cohesin regulates alternative splicing alone or with BRD4

| PRJNA758423 | ENA

A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat

Project description:The purpose of this study was to combine the PDR001 checkpoint inhibitor with several agents with immunomodulatory activity to identify the doses and schedule for combination therapy and to preliminarily assess the safety, tolerability, pharmacological and clinical activity of these combinations.

| 2224182 | ecrin-mdr-crc

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data